Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
Paul E Croarkin, Isabella Sutherland, Ming-Fen Ho
Journal of the American Academy of Child and Adolescent Psychiatry December 19, 2024 DOI: 10.1016/j.jaac.2024.12.003 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Adolescent medicine Psychiatric treatment Youth mental health |
| Citations | 1 |
| Key points | Argues that there is a compelling rationale for rigorous studies of psychedelic-assisted therapy in adolescents aged 16 to 17 years. |
Abstract
We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."1 We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine. We agree that there is a compelling rationale for timely, rigorous studies with adolescents as it is likely that these compounds have been and will be used in adolescents with therapeutic intent. We are writing to catalyze further collegial dialogue and advocacy in our field. We do have some considerations for the authors.